Figure 5: The amount of MRI signal enhancement in the abdominal aorta of atherosclerotic rabbits following treatment with -integrin targeted fumagillin nanoparticles correlates with the therapeutic effect measured 1 week later. This finding suggests that combined imaging and therapeutic nanoparticles can be used to predict the treatment effects at the time of treatment. Reprinted with permission from [35].